Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques

Vaccine

Volumn 35, Issue 4, 2017, Pages 639-646

  Bolton, Diane L ^a   Song, Kaimei ^a   Tomaras, Georgia D ^b   Rao, Srinivas ^a   Roederer, Mario ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aerosol; Immunogenicity; Nasal; Rhesus macaque; Vaccine delivery route

Indexed keywords

ADENOVIRUS VECTOR; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLASMID DNA; VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MUCOSAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; NEBULIZER; NONHUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RESPIRATORY MUCOSA; RESPIRATORY TRACT DISEASE; RHESUS MONKEY; UPPER RESPIRATORY TRACT; VACCINATION; VACCINE IMMUNOGENICITY; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; COMPARATIVE STUDY; CYTOLOGY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; INJECTION; INTRANASAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INJECTIONS; MACACA MULATTA; VACCINES;

EID: 85009290190     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.12.008     Document Type: Article

References (36)

1. [1] Holmgren, J., Czerkinsky, C., Mucosal immunity and vaccines. Nat Med 11 (2005), S45–S53.
2. [2] Johansson, E.L., Wassen, L., Holmgren, J., Jertborn, M., Rudin, A., Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 69 (2001), 7481–7486.
3. [3] Nardelli-Haefliger, D., Lurati, F., Wirthner, D., Spertini, F., Schiller, J.T., Lowy, D.R., et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23 (2005), 3634–3641.
4. [4] Balmelli, C., Roden, R., Potts, A., Schiller, J., De Grandi, P., Nardelli-Haefliger, D., Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72 (1998), 8220–8229.
5. [5] Revaz, S., Dudler, J., Clinical manifestations of gout. Revue medicale suisse 3 (2007), 728–730.
6. [6] de Swart, R.L., Kuiken, T., Fernandez-de Castro, J., Papania, M.J., Bennett, J.V., Valdespino, J.L., et al. Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 24 (2006), 6424–6436.
7. [7] de Swart, R.L., LiCalsi, C., Quirk, A.V., van Amerongen, G., Nodelman, V., Alcock, R., et al. Measles vaccination of macaques by dry powder inhalation. Vaccine 25 (2007), 1183–1190.
8. [8] Bergquist, C., Lagergard, T., Holmgren, J., Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect Immun 65 (1997), 1579–1583.
9. [9] Mills, K.H., Cosgrove, C., McNeela, E.A., Sexton, A., Giemza, R., Jabbal-Gill, I., et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun 71 (2003), 726–732.
10. [10] Belshe, R., Lee, M.S., Walker, R.E., Stoddard, J., Mendelman, P.M., Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Exp Rev Vaccines 3 (2004), 643–654.
11. [11] Song, K., Bolton, D.L., Wei, C.J., Wilson, R.L., Camp, J.V., Bao, S., et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci USA 107 (2010), 22213–22218.
12. [12] Bolton, D.L., Song, K., Wilson, R.L., Kozlowski, P.A., Tomaras, G.D., Keele, B.F., et al. Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunol 5 (2012), 41–52.
13. [13] Wei, C.J., Boyington, J.C., McTamney, P.M., Kong, W.P., Pearce, M.B., Xu, L., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329 (2010), 1060–1064.
14. [14] Cranage, M.P., Fraser, C.A., Cope, A., McKay, P.F., Seaman, M.S., Cole, T., et al. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 29 (2011), 1421–1430.
15. [15] Brough, D.E., Lizonova, A., Hsu, C., Kulesa, V.A., Kovesdi, I., A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70 (1996), 6497–6501.
16. [16] Gall, J.G., Lizonova, A., EttyReddy, D., McVey, D., Zuber, M., Kovesdi, I., et al. Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes. Mol Biotechnol 35 (2007), 263–273.
17. [17] Rasmussen, H., Rasmussen, C., Lempicki, M., Durham, R., Brough, D., King, C.R., et al. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 9 (2002), 951–957.
18. [18] Tomaras, G.D., Yates, N.L., Liu, P., Qin, L., Fouda, G.G., Chavez, L.L., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82 (2008), 12449–12463.
19. [19] Yates, N.L., Stacey, A.R., Nolen, T.L., Vandergrift, N.A., Moody, M.A., Montefiori, D.C., et al. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol 6 (2013), 692–703.
20. [20] Kozlowski, P.A., Lynch, R.M., Patterson, R.R., Cu-Uvin, S., Flanigan, T.P., Neutra, M.R., Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 24 (2000), 297–309.
21. [21] Sprangers, M.C., Lakhai, W., Koudstaal, W., Verhoeven, M., Koel, B.F., Vogels, R., et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41 (2003), 5046–5052.
22. [22] Day, W.C., Berendt, R.F., Experimental tularemia in Macaca mulatta: relationship of aerosol particle size to the infectivity of airborne Pasteurella tularensis. Infect Immun 5 (1972), 77–82.
23. [23] Druett, H.A., Henderson, D.W., Packman, L., Peacock, S., Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hygiene 51 (1953), 359–371.
24. [24] ICRP. Human respiratory tract model for radiological protection.: Elsevier Health Sciences; 1994.
25. [25] Cheng, Y.S., Irshad, H., Kuehl, P., Holmes, T.D., Sherwood, R., Hobbs, C.H., Lung deposition of droplet aerosols in monkeys. Inhalation Toxicol 20 (2008), 1029–1036.
26. [26] Darrah, P.A., Patel, D.T., De Luca, P.M., Lindsay, R.W., Davey, D.F., Flynn, B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 (2007), 843–850.
27. [27] Harari, A., Petitpierre, S., Vallelian, F., Pantaleo, G., Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103 (2004), 966–972.
28. [28] Lin, L., Finak, G., Ushey, K., Seshadri, C., Hawn, T.R., Frahm, N., et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol 33 (2015), 610–616.
29. [29] Seder, R.A., Darrah, P.A., Roederer, M., T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 (2008), 247–258.
30. [30] Da Silva, D.M., Pastrana, D.V., Schiller, J.T., Kast, W.M., Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 290 (2001), 350–360.
31. [31] Liu, X.S., Dyer, J., Leggatt, G.R., Fernando, G.J., Zhong, J., Thomas, R., et al. Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J Immunol 177 (2006), 2873–2879.
32. [32] Zompi, S., Harris, E., Original antigenic sin in dengue revisited. Proc Natl Acad Sci U S A 110 (2013), 8761–8762.
33. [33] Good, M.F., Zevering, Y., Currier, J., Bilsborough, J., ‘Original antigenic sin’, T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion. Parasite Immunol 15 (1993), 187–193.
34. [34] Darrah, P.A., Bolton, D.L., Lackner, A.A., Kaushal, D., Aye, P.P., Mehra, S., et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol 193 (2014), 1799–1811.
35. [35] Dilraj, A., Cutts, F.T., de Castro, J.F., Wheeler, J.G., Brown, D., Roth, C., et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355 (2000), 798–803.
36. [36] Hokey, D.A., Wachholder, R., Darrah, P.A., Bolton, D.L., Barouch, D.H., Hill, K., et al. A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs. Hum Vaccin Immunother 10 (2014), 2199–2210.